Trial Profile
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 (or ABT-493/ABT-530) With and Without Ribavirin in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Failed a Prior Direct-Acting Antiviral Agent (DAA)-Containing Therapy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 30 Jul 2020
Price :
$35
*
At a glance
- Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms MAGELLAN-1
- Sponsors AbbVie; AbbVie Germany
- 16 May 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 03 Apr 2019 New Zealand was planned location as per European Clinical Trials Database.
- 28 Mar 2019 Results assessing the efficacy and safety of Glecaprevir/Pibrentasvir treatment for 8-16 weeks from 9 Phase II and Phase III trials (NCT02243280, NCT02243293, NCT02604017, NCT02640482, NCT02640157, NCT02636595, NCT02642432, NCT02651194, and NCT02446717) published in the Clinical Infectious Diseases.